Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;17(2):280-282.
doi: 10.2215/CJN.04660421. Epub 2021 Dec 6.

Kidney Disease Prevalence in Transgender Individuals

Han E Eckenrode  1 , Orlando M Gutierrez  1 , Gunars Osis  1 , Anupam Agarwal  1   2 , Lisa M Curtis  1
Affiliations

Kidney Disease Prevalence in Transgender Individuals

Han E Eckenrode et al. Clin J Am Soc Nephrol. 2022 Feb.
No abstract available

Keywords: acute kidney injury; chronic kidney disease; kidney; transgender.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
AKI and CKD prevalence rates in the transgender population differ. Prevalence within a population was examined for biologically relevant comparisons. These included (1) a comparison of transfeminine (TF) and transmasculine (TM) to establish a baseline comparison relative to cisgender individuals, (2) a comparison of transfeminine individuals receiving gender-affirming hormone therapy (TFH) and TF to understand the role of exogenous estrogen in modifying prevalence, (3) a comparison of transmasculine individuals receiving gender-affirming hormone therapy (TMH) and TM to explore the role of exogenous testosterone in modifying prevalence, (4) a comparison of TFH with TM to compare exogenous to native testosterone effects on prevalence, (5) a comparison of TMH with TF to compare exogenous and native estrogen effects on prevalence, and (6) a comparison of TFH with TMH to establish sex differences after gender-affirming hormone therapy. (A) AKI had statistically significant differences (P=0.05) between TF (47%) and TM (27%; P=0.005), between TF and TFH (P=0.002), and between TF and TMH (P=0.03). (B) CKD had significant differences between TFH (20%) and TM (49%; P=0.001). Decreases in TFH versus TF and in TMH versus TM did not reach significance (P=0.06 and P=0.05, respectively). *P≤0.05; **P≤0.01
See this image and copyright information in PMC

References

    1. Tangpricha V: Transgender medicine: Best practices and clinical care for the future. Endocrinol Metab Clin North Am 48: xv–xvii, 2019 - PubMed
    1. Lapinski J, Covas T, Perkins JM, Russell K, Adkins D, Coffigny MC, Hull S: Best practices in transgender health: A clinician’s guide. Prim Care 45: 687–703, 2018 - PubMed
    1. Ocon A, Peredo-Wende R, Kremer JM, Bhatt BD: Significant symptomatic improvement of subacute cutaneous lupus after testosterone therapy in a female-to-male transgender subject. Lupus 27: 347–348, 2018 - PubMed
    1. Ramadan OA-O, Naji AA-O, Levine MA-O, Porrett PA-O, Dunn TA-O, Nazarian SA-O, Weinrieb RM, Kaminski M, Johnson D, Trofe-Clark JA-O, Lorincz IA-O, Blumberg EA-O, Weikert BC, Bleicher M, Abt PL: Kidney transplantation and donation in the transgender population: A single-institution case series. Am J Transplant 20: 2899–2904, 2020 - PubMed
    1. Whitley CT, Greene DN: Transgender man being evaluated for a kidney transplant. Clin Chem 63: 1680–1683, 2017 - PubMed

Publication types